<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165087</url>
  </required_header>
  <id_info>
    <org_study_id>95-001</org_study_id>
    <nct_id>NCT00165087</nct_id>
    <nct_alias>NCT00004034</nct_alias>
  </id_info>
  <brief_title>Treatment of Childhood Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Treatment of Childhood Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to reduce the side-effects and discomfort of anti-leukemia&#xD;
      therapy, to attain long-term control of the disease and to hopefully eradicate it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Children with acute lymphoblastic leukemia (ALL) are treated somewhat differently&#xD;
           depending upon on the relative risk of the leukemia recurring. For this study they are&#xD;
           classified into &quot;Standard Risk&quot;, &quot;High Risk&quot; and &quot;Infant/High Risk&quot;.&#xD;
&#xD;
        -  The treatment for patients in the &quot;Standard Risk&quot; and &quot;High Risk&quot; groups consists of&#xD;
           three phases of therapy: induction treatment; prevention of brain and spinal cord&#xD;
           leukemia (CNS treatment); and intensification/continuation chemotherapy.&#xD;
&#xD;
        -  The treatment for patients in the &quot;Infant/High Risk&quot; group consists of four phases of&#xD;
           therapy: induction treatment; infant intensification therapy;&#xD;
           intensification/continuation chemotherapy; and CNS treatment.&#xD;
&#xD;
        -  The induction treatment consists of a combination of chemotherapy drugs whose purpose is&#xD;
           to kill all detectable leukemia cells. This process usually requires a least one month&#xD;
           and includes six anti-leukemia drugs. These drugs are: vincristine, doxorubicin,&#xD;
           methotrexate, cytosine arabinoside, asparaginase and steroids (methylprednisolone or&#xD;
           prednisone).&#xD;
&#xD;
        -  After the induction phase, &quot;Infant/High Risk&quot; patients will receive a highly intensive&#xD;
           month of treatment (infant intensification) . Drugs used during this month include&#xD;
           high-dose methotrexate, asparaginase, 6-mercaptopurine and high dose cytosine&#xD;
           arabinoside (ARA-C).&#xD;
&#xD;
        -  CNS treatment begins during induction therapy but is intensified during the second and&#xD;
           third month after diagnosis. Treatment for all patients will include a series of spinal&#xD;
           taps with the instillation of anti-leukemia drugs, including cytosine arabinoside and&#xD;
           methotrexate and with or without hydrocortisone (depending upon randomization).&#xD;
&#xD;
        -  All high risk patients (those in both &quot;High Risk&quot; and &quot;Infant/High Risk&quot;) as well as&#xD;
           some standard risk patients will receive radiation treatment to the brain. Radiation&#xD;
           therapy will either be given in either &quot;conventional&quot; treatments (once daily for 10&#xD;
           days), or &quot;hyperfractionated&quot; treatments (twice daily at half doses for 10 days). Total&#xD;
           dose of radiation is 1800 cGy.&#xD;
&#xD;
        -  Intensification and continuation therapy, begins 4-5 weeks after diagnosis for &quot;Standard&#xD;
           Risk&quot; and &quot;High Risk&quot; groups and 4-5 weeks after infant intensification in &quot;Infant/High&#xD;
           Risk&quot; group. This phase of treatment continues until the completion of two years of&#xD;
           treatment. Patients in the &quot;Standard Risk&quot; group will receive five anti-leukemia drugs&#xD;
           (vincristine, prednisone, methotrexate, asparaginase, and 6-mercaptopurine). Patients in&#xD;
           &quot;High Risk&quot; and &quot;Infant/High Risk&quot; will receive six anti-leukemia drugs (vincristine,&#xD;
           prednisone, doxorubicin, methotrexate, asparaginase and 6-mercaptopurine).&#xD;
&#xD;
        -  All patients will be able to participate in a randomization comparing two types of&#xD;
           asparaginase, E.coli and Erwinia. Patients will be randomized to receive either once&#xD;
           weekly E.coli or once-weekly Erwinia during the Intensification phase, each given for a&#xD;
           total of 20 weeks.&#xD;
&#xD;
        -  Patients in the &quot;Standard Risk&quot; group are able to participate in an additional&#xD;
           randomization. Standard risk patients will be randomized to receive one of two different&#xD;
           regimens designed to prevent central nervous system leukemia, either 1)radiation therapy&#xD;
           (given twice daily) with chemotherapy in the spinal fluid every 18 weeks, or 2)&#xD;
           intensive chemotherapy in the spinal fluid alone without radiation.&#xD;
&#xD;
        -  Patients in the &quot;High Risk&quot; and &quot;Infant/High Risk&quot; groups are able to participate in two&#xD;
           randomizations in addition to the asparaginase randomization. The first will be to&#xD;
           assess whether the drug dexrazoxane prevents heart damage caused by doxorubicin without&#xD;
           affecting risk of relapse. Patients will be randomized to receive either doxorubicin&#xD;
           alone or doxorubicin with dexrazoxane during the induction, CNS and intensification&#xD;
           phases. The second randomization will compare the relative efficacy and toxicity of&#xD;
           different cranial radiation schedules. Patients will be randomized to receive radiation&#xD;
           in either once daily or twice daily fractions.&#xD;
&#xD;
        -  Blood and bone marrow samples will be collected to learn more about the biology of&#xD;
           leukemia. These samples will also be used to test minimal residual disease levels to&#xD;
           learn if these levels help predict risk of relapse.&#xD;
&#xD;
        -  Quality of life questionnaires will also be performed by the parents of patients, by&#xD;
           children over eight, and by the child's clinician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated by IRB for continuing review&#xD;
  </why_stopped>
  <start_date>January 1996</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-To evaluate the efficacy and safety of doxorubicin with or without dexrazoxane</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-To determine the efficacy of hyperfractionated radiation plus standard intrathecal chemotherapy compared with intensive intrathecal chemotherapy alone in standard risk patients.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-To compare the relative efficacy and toxicity of E.coli and Erwinia asparaginase</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>-To compare the relative efficacy and toxicity of cranial radiation delivered in once-daily versus twice-daily fractions in high risk patinets.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-To compare randomized treatment groups using health-related quality of life analyses.</measure>
  </secondary_outcome>
  <enrollment>491</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase (E. Coli)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase (Erwina)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cranial radiation (once daily fractionation)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cranial radiation (twice-daily fractionation)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal chemotherapy without radiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute lymphoblastic leukemia, excluding known mature B-cell ALL&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Patients who are leukopheresed or exchanged are eligible for study only after&#xD;
             completion of the pheresis or exchange transfusion&#xD;
&#xD;
          -  Absence of a t(8,14) (q24; q32), t (8,22), t(2,8)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.4mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known HIV positive&#xD;
&#xD;
          -  Prior steroid therapy within 30 days of diagnosis&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Ongoing intracranial hemorrhage&#xD;
&#xD;
          -  Clinical evidence of CNS or lung leukostasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen E. Sallan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte Justine Hosptial</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>Santurce</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Lipton JM, Cohen HJ, Sallan SE. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec;14(12):2247-56.</citation>
    <PMID>11187916</PMID>
  </reference>
  <reference>
    <citation>Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 1;97(5):1211-8.</citation>
    <PMID>11222362</PMID>
  </reference>
  <reference>
    <citation>Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 1;21(19):3616-22.</citation>
    <PMID>14512392</PMID>
  </reference>
  <results_reference>
    <citation>Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 8;351(2):145-53.</citation>
    <PMID>15247354</PMID>
  </results_reference>
  <results_reference>
    <citation>Waber DP, Silverman LB, Catania L, Mautz W, Rue M, Gelber RD, Levy DE, Goldwasser MA, Adams H, Dufresne A, Metzger V, Romero I, Tarbell NJ, Dalton VK, Sallan SE. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 1;22(13):2701-7.</citation>
    <PMID>15226337</PMID>
  </results_reference>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <keyword>childhood ALL</keyword>
  <keyword>standard risk</keyword>
  <keyword>high risk</keyword>
  <keyword>infant/high risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Razoxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

